Common adverse drug reactions (≥1% of those treated with the drug) associated with systemic<unk>  therapy include: nausea, diarrhea, weight loss, abdominal pain, vomiting, headache, dizziness, and<unk> allic taste in the mouth. Intravenous administration is commonly associated with thrombophlebitis. Infrequent adverse effects include: hypersensitivity reactions (rash, itch, flushing, fever), headache, dizziness, vomiting, glossitis, stomatitis, dark urine, and paraesthesia. High doses and long-term systemic treatment with<unk>  are associated with the development of leucopenia, neutropenia, increased risk of peripheral neuropathy, and central nervous system toxicity. Common adverse drug reaction associated with topical<unk>  therapy include local redness, dryness and skin irritation; and eye watering (if applied near eyes).<unk>  has been associated with cancer in animal studies. In rare cases, it can also cause temporary hearing loss that reverses after cessation of the treatment. Some evidence from studies in rats indicates the possibility it may contribute to serotonin syndrome, although no case reports documenting this have been published to date. Mutagenesis and carcinogenesis<unk>  is listed by the U.S. National Toxicology Program (NTP) as reasonably anticipated to be a human carcinogen. Although some of the testing<unk> hods have been questioned, oral exposure has been shown to cause cancer in experimental animals and has also demonstrated some mutagenic effects in bacterial cultures. The relationship between exposure to<unk>  and human cancer is unclear. One study found an excess in lung cancer among women (even after adjusting for smoking), while other studies found either no increased risk, or a statistically insignificant risk.<unk>  is listed as a possible carcinogen according to the World Health Organization (WHO) International Agency for Research on Cancer (IARC). A study in those with Crohn's disease also found chromosomal abnormalities in circulating lymphocytes in people treated with<unk> . Stevens–Johnson syndrome<unk>  alone rarely causes Stevens–Johnson syndrome, but is reported to occur at high rates when combined with mebendazole.
Metronidazole
Secnidazole
Fexinidazole
Tinidazole
Benznidazole
Meropenem
Ornidazole
Norfloxacin